This forest plot displays the odds ratios (OR), 95% confidence intervals (CI), numbers of adverse events in the active treatment groups, and numbers of adverse events in the placebo groups for 18 parallel design trials. The sample sizes for each trial are reflected in shaded squares surrounding the OR points. The OR range from 0.50 to 7.39 (pooled OR 1.06 [95% CI 0.96, 1.18]), slightly but not significantly favoring placebo; the studies were not statistically heterogeneous (I-squared 28.0%, p=0.125).

Figure 10Mild upper gastrointestinal adverse events in trials of risedronate versus placebo

From: Results

Cover of Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report
Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report [Internet].
Comparative Effectiveness Reviews, No. 53.
Crandall CJ, Newberry SJ, Diamant A, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.